Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793750 | 1.00 | NOS1 (0.46) | NOS1AXLMETAP2IDO1BRAF | |
| SCHEMBL1473790 | 0.84 | NOS1 (0.46) | NOS1AXLMETAP2IDO1BRAF | |
| SCHEMBL31358108 | 0.83 | METAP2 (0.40) | NOS1AXLMETAP2BRAFEIF2AK3 | |
| SCHEMBL31148280 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL14553409 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL4731645 | 0.83 | METAP2 (0.40) | NOS1AXLMETAP2BRAFEIF2AK3 | |
| SCHEMBL31190700 | 0.76 | NOS1 (0.46) | NOS1METAP2BRAFEIF2AK3MAPK10 | |
| SCHEMBL806451 | 0.76 | MAPT (0.43) | METAP2IDO1BRAFEIF2AK3MAPK10 | |
| SCHEMBL18953590 | 0.76 | METAP2 (0.36) | METAP2IDO1BRAFEIF2AK3MAPK10 | |
| SCHEMBL30860972 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| EP-4608820-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-3560926-A1 | Brk INHIBITORY COMPOUND | Ono Pharmaceutical Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190315756-A1 | BRK INHIBITORY COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190256520-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | disclosed |
| US-10377759-B2 | Brk inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180186800-A1 | BRK INHIBITORY COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3312182-A1 | BRK INHIBITORY COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315756-A1 | BRK INHIBITORY COMPOUND | BRI3BP, BLK, BRSK2 | NOS1 151/4885AXL 3711/4885METAP2 1749/4885 |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | NOS1 4253/4885AXL 1172/4885METAP2 956/4885 |
| US-20180186800-A1 | BRK INHIBITORY COMPOUND | BRI3BP, BRSK2, BLK | NOS1 153/4885AXL 3676/4885METAP2 1930/4885 |
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | NOS1 3139/4885AXL 2838/4885METAP2 3961/4885 |
| US-10377759-B2 | Brk inhibitory compound | BRI3BP, BLK, BRSK2 | NOS1 151/4885AXL 3711/4885METAP2 1749/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | NOS1 1797/4885AXL 3835/4885METAP2 558/4885 |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | NOS1 2755/4885AXL 3670/4885METAP2 3719/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | NOS1 550/4885AXL 3307/4885METAP2 203/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | NOS1 3737/4885AXL 412/4885METAP2 4210/4885 |
| US-20190256520-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | PDXK, PPIP5K2, PCK1 | NOS1 2853/4885AXL 4752/4885METAP2 1131/4885 |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | MALT1, CCR1, CCR6 | NOS1 1233/4885AXL 4163/4885METAP2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.